Subject:
- Active Substance: Olipudase alfa
- Name: Xenpozyme®
- Therapeutic area: Acid sphingomyelinase deficiency (ASMD)
- Pharmaceutical company: Sanofi-Aventis Deutschland GmbH
Time table:
- Start: 01.10.2022
- Final decision by G-BA: 16.03.2023
Final decision:
- Hint for a non-quantifiable additional benefit (orphan drug)